Simulate first, then a human deploys. LIFE OS never deploys on its own.
Interventions
Synthetic demo data
What is working among similar responders
Outcomes of every action among the 284 trajectories most similar to P-03293. Sorted by evidence weight (n × improved share).
| Action | n | Improved | Mean effect | Onset | This patient | |
|---|---|---|---|---|---|---|
| GI-04 GI Support Protocol | 32 | 75% | −20% | 8 d | already tried | Simulate |
| ME-01 Monitoring Escalation | 11 | 100% | −3% | 3 d | eligible · 72% | Simulate |
| SC-12 Supportive Compound | 8 | 100% | −17% | 6 d | eligible · 72% | Simulate |
| DT-01 Dosing / Timing Recommendation | 10 | 80% | −16% | 5 d | eligible · 72% | Simulate |
| NP-02 Dietary Support Protocol | 14 | 57% | −14% | 10 d | eligible · 72% | Simulate |
| CR-01 Clinician Review | 5 | 100% | −18% | 5 d | eligible · 72% | Simulate |
| HY-01 Hydration Protocol | 7 | 43% | −15% | 4 d | eligible · 72% | Simulate |
| BR-03 Behavioural Recommendation | 2 | 100% | −12% | 7 d | eligible · 72% | Simulate |
| AD-05 Adherence Support | 11 | 18% | −6% | 5 d | eligible · 72% | Simulate |
Create intervention
- Cohort
- 1 patients · patient P-03293
Enforcement in the companion
Before deployment
simulationCampaigns
Nothing deployed yet in ONX-7.
Action catalogue
GI-04Nutritional protocol
GI Support Protocol GI-04
symptom −31% · persistence +17% · onset 8 d
SC-12Supportive compound
Supportive Compound SC-12
symptom −18% · persistence +11% · onset 6 d
NP-02Nutritional protocol
Dietary Support Protocol NP-02
symptom −28% · persistence +9% · onset 10 d
HY-01Hydration protocol
Hydration Protocol HY-01
symptom −14% · persistence +6% · onset 4 d
ME-01Monitoring escalation
Monitoring Escalation ME-01
symptom −5% · persistence +12% · onset 3 d
BR-03Behavioural recommendation
Behavioural Recommendation BR-03
symptom −10% · persistence +10% · onset 7 d
CR-01Clinician review
Clinician Review CR-01
symptom −12% · persistence +15% · onset 5 d
AD-05Adherence support
Adherence Support AD-05
symptom −2% · persistence +14% · onset 5 d
DT-01Dosing / timing recommendation
Dosing / Timing Recommendation DT-01
symptom −16% · persistence +8% · onset 5 d